Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New device for dialysis access shows promise in 142 patients

NCT ID NCT04484220

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well the Ellipsys Vascular Access System works for creating arteriovenous (AV) fistulas in people with end-stage kidney disease who need dialysis. A total of 142 patients were followed for 12 months to see how long the access stayed open and how safe the procedure was. The goal was to provide a reliable way to connect an artery and vein for easier dialysis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

142 people

The number who actually took part.

Started

Apr 2021

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or non-pregnant female ≥ 18 years of age and ≤ 80 years of age 2. Life expectancy of at least one year, in the investigator's opinion 3. Diagnosed with ESRD or chronic kidney disease on hemodialysis. 4. Patients deemed medically eligible for upper extremity autogenous AV fistula creation, per institutional guidelines and/or clinical judgment 5. Adequate quality vein based on pre-operative assessment 1. Adjacent vein diameter of ≥2.0 mm at target anastomosis site 2. Confirmed clinically significant outflow 6. Adequate quality radial artery based on pre-operative assessment a. Arterial lumen diameter of ≥2.0 mm at target anastomosis site 7. Adequate collateral arterial perfusion with patent palmar arch as demonstrated by Barbeau Test or Allen's Test. 8. Radial artery-adjacent vein proximity ≤1.5 mm measured lumen edge-to-lumen edge as determined by pre-procedural ultrasound and confirmed pre-procedure 9. Patient is able to provide written informed consent and attend follow-up examinations at the enrolling institution Imaging-based Inclusion Criteria: 10. Confirm radial artery-adjacent vein proximity ≤1.5 mm measured lumen edge-to-lumen edge as determined by pre-procedural ultrasound and confirmed pre-procedurally 11. Confirm radial artery and adjacent vein diameter of ≥2.0 mm at target anastomosis site Exclusion Criteria: 1. Pre-existing ipsilateral vascular disease interfering with the study procedure or potentially confounding the study results including: 1. Documented or suspected central venous stenosis (≥ 50%) or 2. Upper extremity arterial stenosis or 3. Vascular disease at the radial artery / adjacent vein site 2. Prior vascular surgery at or proximal (central) to the AVF target site interfering with AVF maturation or other ipsilateral surgery that could potentially confound the study results such as prior axillary dissection or mastectomy 3. History of steal syndrome from a previous surgical ipsilateral hemodialysis vascular access which required intervention or abandonment 4. Systolic pressures \< 100 mg Hg at the time of screening 5. Suspected or confirmed skin disease at the skin entry site 6. Edema of the upper extremity on the ipsilateral side 7. Immunocompromised subjects due to underlying disease or immunosuppressant therapy such as sirolimus (Rapamune®) or Prednisone at a dose of \> 10 mg per day 8. Known bleeding diathesis, coagulation disorder or medications putting the subject at increased risk, in the Investigator's judgment 9. Patients with acute or active infection 10. Scheduled kidney transplant within 6 months of enrollment 11. Participation in another clinical investigation (excluding retrospective studies or studies not requiring a consent form) 12. History of substance abuse or anticipated to be non-compliant with medical care or study requirements based on investigator judgment 13. Patient has an active COVID-19 infection with ongoing sequela or hospitalization for treatment of COVID-19.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Av fistula are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Azura Vascular Care, Jacksonville

    Jacksonville, Florida, 32218, United States

  • Coastal Vascular and Interventional, PLLC

    Pensacola, Florida, 32504, United States

  • Nephrology Associates Access Center

    Riverside, California, 92501, United States

  • Nephrology Kidney Disease Hypertension Center

    Las Vegas, Nevada, 89128, United States

  • Richmond Vascular Center

    North Chesterfield, Virginia, 23236, United States

  • Rush University Medical Center

    Chicago, Illinois, 60607, United States

  • STAR Vascular Access Center

    San Antonio, Texas, 78207, United States

  • San Antonio Kidney Disease Center

    San Antonio, Texas, 78216, United States

  • Staten Island Hospital

    Staten Island, New York, 10305, United States

  • The Vascular Care Group

    Hyannis, Massachusetts, 022601, United States

  • University of Pittsburg Medical Center

    Pittsburgh, Pennsylvania, 15213, United States

  • Yale University

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.